Richard A Young
CIK 1490283 · last filed 2026-08-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$866.7K
Companies
4
Total Filings
56
Lifetime Open-Market Net
-$1.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 186,388 | $4.65 | $866.7K | $52.0K | 5 | 2026-08-05 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 10,667 | $0.00 | $4 | -$1.35M | 29 | 2024-09-18 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | 739,118 | $0.14 | $105.4K | -$440.0K | 9 | 2024-06-21 |
| Viskase Holdings, Inc. (ENZN) Delisted | Director | 302 | — | — | -$13.8K | 8 | 2013-01-04 |
Recent Filings · Page 5 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-19 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −25,000 | -$250.0K | EDGAR |
| 2019-06-12 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-15 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-22 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-16 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −3,282 | -$72.2K | EDGAR |
| 2017-07-27 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −3,282 | -$72.5K | EDGAR |
| 2017-06-12 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-09-19 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-01-04 | Viskase Holdings, Inc. (ENZN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-07-03 | Viskase Holdings, Inc. (ENZN) Delisted | Grant (A) | +10,669 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.